Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of ibrutinib in mantle cell lymphoma progressing after bortezomib
2012-000711-88Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in mantle cell lymphoma (MCL), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall response rate (IRC-assessed). Started Jun 2012; status: completed.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2012-000711-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000711-88.